Summary & Overview
HCPCS J9289: Nivolumab 2 mg with Hyaluronidase Injection
HCPCS Level II code J9289 identifies an injectable oncology product combining nivolumab (2 mg) with hyaluronidase-nvhy. This biologic formulation is pertinent to cancer immunotherapy and specialty infusion services where monoclonal antibody agents are administered. Nationally, accurate coding of such biologics affects clinical documentation, payer policy application, and facility billing for high-cost cancer therapies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of what the code represents, typical sites of service, and the clinical context for nivolumab with hyaluronidase. The publication outlines common billing considerations and the kinds of benchmarks and policy topics typically associated with high-cost injectable oncology agents, including coverage policy variation, site-of-care implications, and documentation elements necessary for claims adjudication.
This summary provides a national perspective intended to orient clinicians, coding professionals, and policy analysts to the code's role in practice and reimbursement workflows. Data not available in the input will be identified as such in relevant sections.
Billing Code Overview
HCPCS Level II code J9289 describes an injectable medication pairing of nivolumab, 2 mg, and hyaluronidase-nvhy. The entry denotes the drug product and unit measure for administration of nivolumab formulated with hyaluronidase, used in oncology and immunotherapy contexts.
Service Type: Therapeutic injection / infusion of a monoclonal antibody formulation
Typical Site of Service: Hospital outpatient departments, oncology infusion centers, and specialty clinics
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with an advanced or metastatic malignancy for which immune checkpoint inhibition with nivolumab is indicated (for example, unresectable or metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, or urothelial carcinoma). The medication billed with J9289 is a formulation of nivolumab combined with hyaluronidase (hyaluronidase-nvhy) intended for subcutaneous administration to facilitate dispersion and absorption. The clinical workflow: the oncology clinic documents the treatment plan and confirms indication and prior authorization if required by the payer; baseline evaluation and consent are obtained; vitals and allergy review are performed; the nurse prepares the J9289 dose according to prescribing information and administers subcutaneously in an appropriate site (typically the abdomen or thigh) with standard infection-control technique; the patient is observed for infusion- or injection-related reactions for the recommended observation period; toxicity monitoring (immune-related adverse events) is scheduled with follow-up labs and visits; each administration visit is documented with drug name, NDC if required, dose, route, site, lot number, and any modifier(s) to reflect circumstance (for example, JW for discarded drug when applicable). Typical sites of service are outpatient oncology infusion/clinic or physician office with capability to monitor for immune-related reactions. Common clinical modifiers recorded include outpatient status, administration complexity, and discarded drug adjustments.
Coding Specifications
| Modifier | Description | When to Use |
|---|